Fig. 1From: Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in SpainFirst-line a overall survival (OS) and b progression-free survival (PFS) in the overall populationBack to article page